Evidence map›Paper›PMID 42237660›Full record

ArticleBlood2026

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

Christopher S Hourigan, Lisanne Beugelink, Jad Othman, Gege Gui, Adam Ivey, Richard Dillon, Christian Thiede, Mark J Levis, Laura W Dillon, Andrew H Wei and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. FLT3-ITD MRD is here to stay.Blood advances · 2026
    Article
  2. Article
  3. Cancers · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Christopher S HouriganFralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute Cancer Research Center, Washington, DC.ORCID 0000-0002-6189-8067
Lisanne BeugelinkErasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.ORCID 0000-0001-8303-9338
Jad OthmanThe University of Sydney, Sydney, Australia.ORCID 0000-0002-4971-3576
Gege GuiFralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute Cancer Research Center, Washington, DC.
Adam IveyAlfred Hospital, Melbourne, VIC, Australia.
Richard DillonKing's College London, London, United Kingdom.
Christian ThiedeUniversity Hospital, Dresden University of Technology, Dresden, Germany.ORCID 0000-0003-1241-2048
Mark J LevisJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.ORCID 0000-0003-0473-6982
Laura W DillonFralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute Cancer Research Center, Washington, DC.ORCID 0000-0002-4877-9354
Andrew H WeiPeter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia.ORCID 0000-0002-7514-3298
Ing Soo TiongPeter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia.ORCID 0000-0001-7417-4343
Sun LooAlfred Hospital, Melbourne, VIC, Australia.ORCID 0000-0001-6294-2691
Konstanze DöhnerUniversity Hospital of Ulm, Ulm, Germany.
Isabell ArnhardtHannover Medical School, Hannover, Germany.ORCID 0009-0003-5378-4523
Artur KowalikHoly Cross Cancer Center, Kielce, Poland.ORCID 0000-0002-3718-999X
Nicola PotterKing's College London, London, United Kingdom.ORCID 0000-0002-8256-9350
Dennis Dong Hwan KimPrincess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Claude PreudhommeUniversity Hospital of Lille, Lille, France.ORCID 0000-0002-1267-9546
Nicolas DuployezUniversity Hospital Center of Lille, University of Lille, INSERM U1366, Lille, France.ORCID 0000-0002-3927-1022
Michael HeuserHannover Medical School, Hannover, Germany.ORCID 0000-0001-5318-9044
Peter J M ValkErasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractFLT3-internal tandem duplication measurable residual disease testing for patients in remission from acute myeloid leukemia is now recommended by the recently updated clinical standard-of-care guidelines. This companion technical note provides important laboratory and clinical recommendations regarding such testing.

Indexed as

fms-Like Tyrosine Kinase 3High-Throughput Nucleotide SequencingLeukemia, Myeloid, AcuteNeoplasm, ResidualTandem Repeat SequencesHumansFLT3 protein, humanfms-Like Tyrosine Kinase 3

Identifiers

PMID42237660
PMCPMC13487476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.